Primary Biliary Cholangitis Therapeutics Market Size

Primary biliary cholangitis therapeutics Market Size

Primary Biliary Cholangitis Therapeutics Market size was valued at USD 677.2 million in 2023 growing at a CAGR of 7.1% between 2024 and 2032, driven by factors such as the increase in the prevalence of primary biliary cholangitis.

To get key market trends

  Download Free Sample

For instance, as per the report published by Haymarket Media, Inc., it has been reported that the incidence and prevalence of PBC differ by geographic location such as the North America has the highest prevalence (21.81 per 100,000 individuals), followed by Europe (14.59 per 100,000 persons). The Asia-Pacific region had the lowest prevalence at 9.82 per 100,000 persons. Thus, the increasing prevalence of primary biliary cholangitis, especially among middle-aged women, drive the demand for effective treatments that is anticipated to boost the growth of the market.
 

Moreover, surge in technological advancement in diagnostic devices enable earlier and more accurate detection of PBC, leading to timely treatment and better patient outcomes, thereby augmenting the market growth.
 

Therapeutics for PBC focus on managing symptoms, slowing disease progression, and addressing complications. Ursodeoxycholic acid (UDCA) is the first-line treatment, helping improve bile flow, reduce liver inflammation, and delay disease progression, though it may not be effective for all patients. Obeticholic acid (OCA), a second-line treatment, is used for those with inadequate response to UDCA and works by reducing bile acid synthesis and improving bile flow.